FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

Science & Research
6

Evidence-Based Look at Thymosin Alpha-1

Petra Harrison·7 months ago
Evidence-based assessment of Thymosin Alpha-1 — what the data supports and where we need more information. Level of evidence summary: Strong evidence (multiple RCTs or meta-analyses): Thymosin Alpha-1 improves specific biomarkers related to its mechanism of action. Moderate evidence (single RCT or consistent observational data): improvements in functional outcomes related to recovery and tissue health. Weak evidence (case reports, preclinical only): some of the broader health claims circulating online. The preclinical-to-clinical translation for Thymosin Alpha-1 has actually been better than average for the peptide therapeutics space. Effects seen in animal models have generally been reproducible in humans, though with expected reductions in magnitude. I want to highlight the dose-response relationship because it is important for practical application. The available data suggests a sigmoidal dose-response curve with a clear minimum effective dose and a plateau beyond which additional dose provides minimal additional benefit. This means more is not necessarily better, and the commonly discussed dose ranges appear to be well-positioned on the dose-response curve. Future research directions that I find most exciting include biomarker-guided dosing (personalizing the protocol based on individual response markers) and combination protocols that leverage mechanistic synergies between Thymosin Alpha-1 and complementary compounds. The science is solid. Let us keep the discussion grounded in what it actually shows.

Comments (3)

Jordan HardingDEMO·7 months ago

Solid protocol. One suggestion: consider adding HRV tracking if you are not already. It has been the most objective and responsive metric for me during my Thymosin Alpha-1 protocol. Changes in HRV preceded subjective improvements by about a week, which gave me early confidence the protocol was working.

7
Cloud GarrettDEMO·7 months ago

Your point about consistency being more important than optimization really resonates. I wasted weeks early in my Thymosin Alpha-1 journey tweaking doses and timing when I should have just picked a reasonable protocol and stuck with it. The best results came when I stopped overthinking and just stayed consistent.

2
Chris GomezDEMO·7 months ago

This is a great discussion about Thymosin Alpha-1. I want to add that I found morning dosing on an empty stomach gave me noticeably better results than evening dosing. Tried both for 4 weeks each. The difference was subtle but consistent across my tracking metrics.

3

Sign in to comment.